Kal Patel, MD has over 20 years of experience in pharma, medtech and regulated digital health.
He currently serves as CEO and Co-Founder at BrightInsight, the leading global platform for biopharma and medtech regulated digital health solutions. BrightInsight has raised $166M in financing from world-renowned venture capital firms including General Catalyst, Insight Partners, New Leaf Venture Partners, and Eclipse Ventures, and attracted some of the world’s top biopharma and medtech companies as customers including Sanofi, Novo Nordisk, AstraZeneca, UCB and CSL Behring, among others.
Prior to founding BrightInsight he was Chief Commercial Officer for Doctor on Demand, now one of the nation’s largest video-medicine provider, with backing from Andreessen Horowitz, Venrock, Google Ventures, and Qualcomm.
Kal founded and built Amgen’s Digital Health business unit where he had end-to-end responsibility for developing and commercializing a portfolio of regulated digital products including connected devices, Software as a Medical Device (SaMD), and algorithms.
Prior to his focus on digital health at Amgen, Kal was the Global Marketing Lead for Enbrel, the company’s leading drug with over $6B in sales, where he created and launched major investments in novel clinical trials, innovative drug delivery devices, improved formulations and differentiated patient support programs. Kal started his Amgen career as Head of Corporate Strategy.
Kal also spent several years at Novartis Pharmaceuticals in various sales, marketing and account leadership roles. He began his professional career at the Boston Consulting Group where he worked for a broad portfolio of Healthcare companies across the U.S. and Europe. He transferred to the company’s Budapest office as part of BCG’s prestigious Ambassador program and was promoted early to Principal. Kal has also served as a Senior Advisor in Digital Health to the Boston Consulting Group where he helped C-level executives at pharma and medtech companies develop and execute digital health strategies.